This task order (to) is to provide dosage form development, manufacture and stability studies of ORC-13661 for phase II clinical trial
Ended Awarded Last action
- Contract number
- 75N95022F00001
- Awardee
-
Societal Cdmo San Diego, LLC UEI YRPTVKHDL7Z5
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $735,749
Award facts
- Opportunity
-
- 75N95022R00075 Solicitation number
- Contract value 97% obligated
-
- $735,749.00 Current, with exercised options
- $760,749.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92121, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | $0 | |
| Exercise an Option | $180,000 | |
| Original award | $555,749 |
About this award
This is a $760,749 firm fixed-price delivery order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency within the National Institutes of Health, to Societal CDMO San Diego, LLC (doing business as Irisys Inc.). The order is to provide dosage form development, manufacturing, and stability studies of the investigational drug ORC-13661 for a Phase II clinical trial. This delivery order was issued under the NCATS Drug Product Development Studies 2017-2022 indefinite delivery/indefinite quantity (IDIQ) contract vehicle. The award is not set aside for any specific business categories, indicating Societal CDMO's competitive capabilities in pharmaceutical manufacturing and development. Societal CDMO is a self-certified small disadvantaged business structured as a for-profit limited liability company and a subsidiary of Recro Pharma, Inc. The company has extensive experience providing specialized pharmaceutical services to federal agencies, particularly within the NIH ecosystem, including developing and manufacturing investigational drugs for clinical research.
Quick answers
Who was awarded contract 75N95022F00001?
75N95022F00001 was awarded to Societal Cdmo San Diego, LLC by National Institute on Drug Abuse (National Institutes of Health) on September 27, 2022.
How much is contract 75N95022F00001 worth?
The government has obligated $735,749 on 75N95022F00001. Its potential value, with all options, is $760,749.
Is contract 75N95022F00001 an order under another contract?
Yes. 75N95022F00001 is a delivery order under HHSN271201700020I, an indefinite delivery contract, on NCATS Drug Product Development Studies 2017-2022.
Was contract 75N95022F00001 competed?
The extent of competition for 75N95022F00001 was full and open competition. The government received 4 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award